An interventional study of OnabotulinumtoxinA and Greater Occipital Nerve Block (GONB) in Chronic Migraine Headache, OnabotulinumtoxinA and Greater Occipital Nerve Block, sponsored by Beni-Suef University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Beni-Suef University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing botulinum toxin type A in Migraine Disorders — 6 open to participants now, 10 under way, 5 of them phase 3. botulinum toxin type A · Migraine Disorders.
Among the 39 studies testing botulinum toxin type A in Migraine Disorders, this one is the 18th largest by planned enrollment, is one of 3 that started in 2026, is one of 5 with no phase, and was the 37th registered.
1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →6 of the 39 studies testing botulinum toxin type A in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 18–65
Naval Medical Center Camp Lejeune · Sites in United States
Ages 18–89
Assiut University
Ages 18–65
Assiut University
Ages 18–65
Europainclinics z.ú.
Ages 18–80
By country, each count listing its studies:
botulinum toxin type A: first FDA approval 1991 (BOTOX COSMETIC), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 14 · Phase 4 12
First in 2003; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.
Median enrollment 70 across the 39 interventional studies. Of the 25 that completed or were terminated, 17 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 39 have an industry lead sponsor. The 10 most frequent:
Beni-Suef University is the lead sponsor of 350 studies on the registry; 124 are open to participants now.
Beni-Suef University has 4 studies filed under Migraine Disorders — fewer than ten, so there is no comparison to draw.
4 of the studies testing botulinum toxin type A in Migraine Disorders that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05598723Phase 3Naval Medical Center Camp LejeuneBOTOX® vs. XEOMIN® for Chronic Migraine | 2027-02-24 |
| NCT07018700Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine | 2027-03 |
| NCT07018713Phase 3Merz Therapeutics GmbHA Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine | 2027-03 |
| NCT07837570Assiut UniversityComparison of the Effectiveness of Greater Occipital Nerve and Supratrochlear Nerve Pulsed Radiofrequency Versus Botulinum Toxin Type A Injection in Chronic Migraine | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 39 studies testing botulinum toxin type A in Migraine Disorders, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Chronic migraine is a debilitating neurological disorder that significantly affects patients' daily functioning, mental health, and quality of life. Management typically includes acute and preventive treatments, but effectiveness can be limited due to medication overuse or delayed onset of action. OnabotulinumtoxinA injections provide proven long-term preventive benefits, while Greater Occipital Nerve (GON) block offers rapid but short-term relief. Although both treatments are used individually, evidence on the combined effect is limited. This randomized controlled trial aims to evaluate the efficacy and safety of combining OnabotulinumtoxinA injections with GON block, assessing improvements in headache frequency, severity, and patient quality of life compared to single therapy.
Chronic migraine is a disabling neurological disorder that affects a significant proportion of the population, leading to substantial functional, psychological, and economic burdens. Despite the availability of acute and preventive treatments, many patients continue to experience frequent headaches due to limited efficacy, delayed onset of action, or medication overuse.
OnabotulinumtoxinA injections have been shown to provide sustained preventive benefits in chronic migraine, reducing headache frequency and improving patient quality of life. Greater Occipital Nerve (GON) block offers rapid relief of headache symptoms, though the effect is typically short-term. While both interventions are used individually, there is limited evidence on the benefits of combining them to achieve both immediate and sustained symptom control.
This randomized controlled trial aims to evaluate the safety and efficacy of combining OnabotulinumtoxinA injections with GON block in adult patients with chronic migraine. Participants will be randomly assigned to one of the following groups: OnabotulinumtoxinA alone, GON block alone, combined therapy, or standard care. Headache frequency, severity, duration, and patient-reported quality of life will be assessed over a 12-week follow-up period. Adverse events and tolerability will also be recorded systematically.
The study is conducted under the supervision of an independent ethics committee to ensure participant safety and adherence to Good Clinical Practice standards. Findings from this study aim to provide evidence on whether an integrated therapeutic approach can offer superior relief and improve long-term outcomes for patients with chronic migraine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: OnabotulinumtoxinA · Procedure: Greater Occipital Nerve Block (GONB)
OnabotulinumtoxinA will be injected intramuscularly at standard PREEMPT injection sites for chronic migraine prophylaxis. Total dose per session: 155 units distributed across 31 sites.
Drug: OnabotulinumtoxinA
Injection of local anesthetic (2% lidocaine, 1-2 mL per side) around the greater occipital nerve at the occipital region. Procedure performed by trained neurologist.
Procedure: Greater Occipital Nerve Block (GONB)
OnabotulinumtoxinA will be injected intramuscularly at standard PREEMPT injection sites for chronic migraine prophylaxis. Total dose per session: 155 units distributed across 31 sites.
Injection of local anesthetic (2% lidocaine, 1-2 mL per side) around the greater occipital nerve at the occipital region. Procedure performed by trained neurologist
Proportion of participants achieving ≥50% reduction in monthly migraine days (MMD)
Responder rate defined as the proportion of participants achieving a ≥50% reduction in monthly migraine days compared to baseline, as recorded in headache diaries
Time frame: 1 month and 3 months after treatment
Time to achieve ≥30% reduction in monthly migraine days (MMD)
Time from treatment initiation to the first occurrence of a ≥30% reduction in monthly migraine days compared to baseline
Time frame: Up to 3 months after treatment
Change in Headache Impact Test (HIT-6) score
Change from baseline in Headache Impact Test (HIT-6) total score (range: 36-78), where higher scores indicate greater headache-related disability and worse outcomes
Time frame: Baseline, 1 month, and 3 months after treatment
Change in Allodynia Symptom Checklist (ASC-12) score
Change from baseline in Allodynia Symptom Checklist (ASC-12) total score (range: 0-24), where higher scores indicate more severe cutaneous allodynia
Time frame: Baseline, 1 month, and 3 months after treatment
Change in Migraine Interictal Burden Scale (MIBS-4) score
Change from baseline in Migraine Interictal Burden Scale (MIBS-4) total score (range: 0-12), where higher scores indicate greater interictal burden
Time frame: Baseline, 1 month, and 3 months after treatment
Change in acute migraine medication use
Change from baseline in the frequency of acute migraine medication use as recorded in patient diaries
Time frame: Baseline, 1 month, and 3 months after treatment
Patient Global Impression of Change (PGIC)
Patient Global Impression of Change (PGIC) measured using a 7-point Likert scale (range: 1-7), where higher scores indicate greater improvement
Time frame: 1 month and 3 months after treatment
Short Assessment of Patient Satisfaction (SAPS) score
Patient satisfaction measured using the Short Assessment of Patient Satisfaction (SAPS) total score (range: 0-28), where higher scores indicate greater patient satisfaction
Time frame: 1 month and 3 months after treatment
Incidence of adverse events
Number and severity of treatment-related adverse events (local and systemic)
Time frame: Up to 3 months after treatment
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Start is estimated for Apr 2026; primary completion for Oct 2026, 6 months later.
Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 6 months is below that.
Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A